CRISPR Therapeutics stock initiated with Overweight rating by JPMorgan

Investing.com - CRISPR Therapeutics (NASDAQ:CRSP) received an Overweight rating initiation from JPMorgan on Thursday, with a price target of $70.00. The stock, currently trading at $59.07, has shown strong momentum with a 50% gain year-to-date. According to InvestingPro data, analysts maintain a moderately bullish consensus on the stock.

The rating reflects JPMorgan’s view that CRISPR Therapeutics "warrants a new look from investors" as the company approaches "several inflection points across its portfolio."

JPMorgan highlighted that CRISPR Therapeutics’ position differs significantly from most gene-editing peers, with its partnered Casgevy product and approximately $2 billion cash reserve offering "good valuation support." InvestingPro analysis confirms the company’s strong liquidity position, with a current ratio of 16.61 and more cash than debt on its balance sheet. Get access to 13 additional ProTips and comprehensive financial analysis with InvestingPro.

The firm expects Casgevy sales to "take off" with net profits beginning to flow into CRISPR Therapeutics in the near term, creating value for the company’s stake in the franchise.

JPMorgan also noted the "prospect of a milder preconditioning" as an additional factor contributing to the company’s "attractive potential."

In other recent news, CRISPR Therapeutics reported a significant earnings miss for the second quarter of 2025, with a loss of $2.40 per share compared to the analyst estimate of $1.40 per share. The company’s revenue for the quarter was $890,000, falling short of the projected $5.81 million. This shortfall was mainly due to higher-than-expected research and development expenses of $96.3 million, associated with a recent agreement with Sirius Therapeutics. Despite these results, H.C. Wainwright raised its price target for CRISPR Therapeutics to $80.00 from $65.00, maintaining a Buy rating, following a 114% increase in CASGEVY sales to $30 million in the same quarter. Barclays also raised its price target to $56.00 from $42.00, citing pipeline progress and maintaining an Equalweight rating. Barclays described the earnings release as "largely incremental," noting updates on the Casgevy treatment after Vertex Pharmaceuticals’ earnings report. These developments reflect a mixed outlook for the company, with financial challenges offset by strategic advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.